Sem A.O.F. Rikken graduated as MD at the University of Groningen, and currently holds a PhD position at the Cardiovascular Research Insitute of Maastricht, working mainly at the Center for Platelet Function Studies at the department of Cardiology in the St. Antonius hospital, Nieuwegein, the Netherlands.
The novel subcutaneously administered glycoprotein IIb/IIIa antagonist RUC-4 (Zalunfiban) did not cause thrombocytopenia in the phase 2a study of patients with ST-elevation myocardial infarction
Event: ESC Acute CardioVascular Care 2022
Topic: Pharmacotherapy
Session: Anti-thrombotic management in patients with acute coronary syndromes (ACS)
ESC 365 is supported by
